| __timestamp | GSK plc | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8246000000 | 35942000 |
| Thursday, January 1, 2015 | 9232000000 | 40028000 |
| Friday, January 1, 2016 | 9366000000 | 45853000 |
| Sunday, January 1, 2017 | 9672000000 | 53816000 |
| Monday, January 1, 2018 | 9915000000 | 60804000 |
| Tuesday, January 1, 2019 | 11402000000 | 77252000 |
| Wednesday, January 1, 2020 | 11456000000 | 45736000 |
| Friday, January 1, 2021 | 10975000000 | 50323000 |
| Saturday, January 1, 2022 | 8372000000 | 143526000 |
| Sunday, January 1, 2023 | 9385000000 | 149182000 |
Unlocking the unknown
In the competitive world of pharmaceuticals and biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, GSK plc and Halozyme Therapeutics, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, GSK's SG&A expenses fluctuated, peaking in 2020 with a 39% increase from 2014, before dropping by 27% in 2022. Meanwhile, Halozyme's expenses grew steadily, with a notable 315% increase by 2023 compared to 2014. This divergence highlights GSK's focus on cost control amidst market challenges, while Halozyme's rising expenses reflect its aggressive growth strategy. Understanding these trends offers valuable insights into how these companies navigate financial management in a dynamic industry.
Selling, General, and Administrative Costs: Pfizer Inc. vs GSK plc
Sanofi or GSK plc: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: GSK plc vs ADMA Biologics, Inc.
GSK plc vs Amicus Therapeutics, Inc.: SG&A Expense Trends
GSK plc and Merus N.V.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: GSK plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or Perrigo Company plc
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or Ligand Pharmaceuticals Incorporated
Halozyme Therapeutics, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.